The group led by Andrés Muñoz (Gregorio Marañón Hospital, Madrid) has published a subanalysis of the ONCOTHROMB12-01 study, which examines the impact of a diagnosis of venous thromboembolic disease (VTE) on the overall survival of cancer patients. A diagnosis of VTE was associated (independently of tumor type and stage) with worse overall survival, suggesting an unfavorable and more aggressive tumor biology.

Specifically, in the subgroup of patients with pancreatic cancer, 18-month survival was 12.7% in patients with a thrombotic event compared with 54.1% in those without thrombosis (p < 0.0001). The incidence of VTE in the pancreatic cancer cohort was 28.3% at 12 months and 35.9% at 18 months. In patients who experienced a second thrombotic episode, the impact on survival was even greater: 18-month survival was 69.4% in patients without thrombosis, 46.5% in those with thrombosis, and 18.2% in those with recurrent thrombosis (p < 0.0001). Unfortunately, no molecular information is available for the pancreatic tumors included in the study.

For more information about the article 📃👉 link